

# Incontinence Associated Dermatitis with Suspected Infection

Incorporating the Ghent Global IAD Categorisation Tool (GLOBIAD)<sup>1</sup> and **Antimicrobial Stewardship Recommendations**

Incontinence Associated Dermatitis (IAD) is the skin damage associated with exposure to urine or faeces.

**RISK FACTORS INCLUDE** ■ **incontinence** ■ use of occlusive containment products ■ compromised mobility ■ damaged skin integrity ■ diminished cognitive awareness ■ inability to perform personal hygiene ■ pain ■ raised body temperature ■ poor nutrition ■ medications (eg: immunosuppressants) ■ critical illness ■ poor hygiene ■ inappropriate application of barrier cream ■ comorbidities (eg: **diabetes\***)

| ASSESSMENT   |  |  | MANAGEMENT   |  |
|--|--|--|--|--|
| CATEGORY   | CRITICAL CRITERIA  | ADDITIONAL CRITERIA  | CORE MEASURES<br>Use for all IAD categories  | TARGETED MEASURES<br>Use in addition to core measures  |
| <b>1A: Persistent redness WITHOUT clinical signs of infection</b><br> | <ul style="list-style-type: none"> <li><b>Persistent redness</b><br/>A variety of tones of redness may be present. In persons with darker skin tones, the skin may be paler or darker than normal, or purple in colour.</li> </ul>   | <ul style="list-style-type: none"> <li>Marked areas or discolouration from a previous (healed) skin defect</li> <li>Shiny appearance of the skin</li> <li>Macerated skin</li> <li>Intact vesicles or bullae</li> <li>Skin may feel tense or swollen at palpation</li> <li>Burning, tingling, itching or pain</li> </ul>  | <ul style="list-style-type: none"> <li>Investigate for and manage the preventable causes of incontinence such as urinary tract infection, faecal impaction, excessive urine output, delirium etc.<sup>2</sup></li> <li>Screen for pressure injury risk and manage accordingly.<sup>3</sup></li> </ul> <p><b>MONITOR, CLEANSE, PROTECT, RESTORE and MONITOR again.</b></p> <p><b>ALL persons who are incontinent require a skin management regime</b></p> | <p><b>Persistent redness WITHOUT clinical signs of infection</b></p> <ul style="list-style-type: none"> <li>Do <b>NOT</b> prescribe antimicrobial agents, including antifungal creams.</li> </ul>  |
| <b>1B: Persistent redness WITH clinical signs of infection</b><br>    | <ul style="list-style-type: none"> <li><b>Persistent redness:</b> As above.</li> <li><b>Signs of infection:</b> such as                             <ul style="list-style-type: none"> <li>White scaling of the skin (suggesting a fungal infection)</li> <li>Satellite pustule lesions (suggesting a Candida albicans fungal infection).</li> </ul> </li> </ul>   | <ul style="list-style-type: none"> <li>Marked areas or discolouration from a previous (healed) skin defect</li> <li>Shiny appearance of the skin</li> <li>Macerated skin</li> <li>Intact vesicles or bullae</li> <li>Skin may feel tense or swollen at palpation</li> <li>Burning, tingling, itching or pain</li> </ul>  | <ul style="list-style-type: none"> <li>Use soap-free pH adjusted cleansers, 'no-rinse' wipes or '3-in-1' wipes after each episode of incontinence.</li> <li>Avoid rubbing - pat skin dry.</li> <li>Apply a skin barrier product according to the manufacturer's instructions.</li> <li>Use barrier products that are transparent and easily removed to allow for skin inspection.</li> <li>Avoid using powders.</li> </ul>                               | <p><b>Persistent redness WITH clinical signs of infection</b></p> <ul style="list-style-type: none"> <li>See medication therapy (page 2):                             <ul style="list-style-type: none"> <li>-If suspected fungal infection, apply antifungal cream.</li> <li>-If suspected bacterial infection, administer antibiotics.</li> </ul> </li> <li>Apply barrier product after antifungal cream (see page 2).</li> <li>Document the reason, name, dose, route of administration, (if topical, exact site of application), intended duration and review plan for each prescribed medication.</li> <li>Refer to a Continence Advisor or Wound Specialist/Consultant (with dedicated hours for this role) if no improvement after 3-5 days.</li> </ul>   |
| <b>2A: Skin loss WITHOUT clinical signs of infection</b><br>         | <ul style="list-style-type: none"> <li><b>Skin loss</b><br/>May present as skin erosion (may result from damaged/eroded vesicles or bullae), denudation or excoriation. The skin damage pattern may be diffuse.</li> </ul>   | <ul style="list-style-type: none"> <li>Persistent redness.</li> <li>A variety of tones of redness may be present. In persons with darker skin tones, the skin may be paler or darker than normal, or purple in colour.</li> <li>Marked areas or discolouration from a previous (healed) skin defect</li> <li>Shiny appearance of the skin</li> <li>Macerated skin</li> <li>Intact vesicles or bullae</li> <li>Skin may feel tense or swollen at palpation</li> <li>Burning, tingling, itching or pain</li> </ul> | <ul style="list-style-type: none"> <li>Use products that do not interfere with absorption or function of continence aids (for example petrolatum containing products).</li> <li>If skin is dry, apply a topical leave-on skin moisturiser to support restoration of the skin barrier function.<sup>2</sup></li> <li>Use continence aids that are well fitted, reduce humidity and have a superior wicking ability.</li> </ul>                            | <p><b>Skin loss WITHOUT clinical signs of infection</b></p> <ul style="list-style-type: none"> <li>Do <b>not</b> prescribe antimicrobial agents, including antifungal creams.</li> </ul>   |
| <b>2B: Skin loss WITH clinical signs of infection</b><br>           | <ul style="list-style-type: none"> <li><b>Skin loss:</b> As above</li> <li><b>Signs of infection:</b> such as                             <ul style="list-style-type: none"> <li>White scaling of the skin (suggesting a fungal infection)</li> <li>Satellite pustule lesions (suggesting a Candida albicans fungal infection).</li> <li>Slough (yellow/brown/greyish) visible in the wound bed</li> <li>Green appearance within the wound bed, suggesting a Pseudomonas aeruginosa (bacterial) infection,</li> <li>Excessive exudate levels,</li> <li>Purulent exudate (pus), or</li> <li>Shiny appearance of the wound bed.</li> </ul> </li> </ul> | <ul style="list-style-type: none"> <li>Persistent redness.</li> <li>A variety of tones of redness may be present. In persons with darker skin tones, the skin may be paler or darker than normal, or purple in colour.</li> <li>Marked areas or discolouration from a previous (healed) skin defect</li> <li>Shiny appearance of the skin</li> <li>Macerated skin</li> <li>Intact vesicles or bullae</li> <li>Skin may feel tense or swollen at palpation</li> <li>Burning, tingling, itching or pain</li> </ul> | <ul style="list-style-type: none"> <li>See medication therapy (page 2): Consider using topical steroids only to manage inflammation and pain.<sup>3</sup></li> <li>Inspect affected skin at least twice daily and document observations/ actions.</li> <li>Consider referral to an employed Continence Advisor.</li> </ul>   | <p><b>Skin loss WITH clinical signs of infection</b></p> <ul style="list-style-type: none"> <li>See medication therapy (page 2):                             <ul style="list-style-type: none"> <li>-If suspected fungal infection, apply antifungal cream.</li> <li>-If suspected bacterial infection, administer antibiotics.</li> </ul> </li> <li>Apply barrier product after antifungal cream (see page 2).</li> <li>Document the reason, name, dose, route of administration, (if topical, exact site of application), intended duration and review plan for the prescribed medication(s).</li> <li>Take microbiology samples only for suspected bacterial infections. Clean first before swabbing at exudate site.</li> <li>Refer to a Continence Advisor or Wound Specialist/Consultant (with dedicated hours for this role) if no improvement after 3-5 days.</li> </ul> |

\* 1. If on an SGLT2 inhibitor, refer to GP for cessation of medication. 2. If BGL > 10 mmol per litre (and not on an SGLT2 inhibitor) refer to a Credentialed Diabetes Educator

**Differential diagnosis**

It is important to exclude pressure injuries, dermatologic conditions (e.g. psoriasis), other bacterial and viral (e.g. herpes zoster) infections



## Targeted medication therapy<sup>4,5,6</sup>

### To treat cutaneous (skin) candidiasis:

- Bifonazole 1% cream topically, once daily for 2 weeks, or
  - Clotrimazole 1% cream topically, twice daily for 2 weeks, or
  - Econazole 1% cream topically, twice daily for 2 weeks, or
  - Miconazole 2% cream topically, twice daily for 2 weeks, or
  - Nystatin 100 000 units/g cream topically, twice daily for 2 weeks.
- Although cream must be well applied (it should not be visible), avoid vigorous rubbing
  - Do not discontinue cream application when fungal infection signs +/- symptoms resolve; continue to apply as prescribed.

### Consider using topical steroid for short term management of severe inflammation (and pain):

- Hydrocortisone 1% cream topically, twice daily.
- If using a combined antifungal and steroid agent, when inflammation subsides continue treatment with an antifungal agent alone.<sup>5</sup>
- Use the least potent topical corticosteroid product required to control the skin disorder for the shortest time possible.<sup>6</sup>

### If the response to a topical antifungal drug is poor, or topical treatment is impractical, oral therapy is appropriate:

- Fluconazole 150 mg orally, as a single dose.

### To treat mild cellulitis or erysipelas:

- Di/flucloxacillin 500 mg orally 6 hourly for 5 to 10 days.

If *S.pyogenes* is isolated from cultures, or suspected based on clinical presentation or local epidemiology use

- Phenoxyethylpenicillin 500mg orally 6 hourly for 5 to 10 days, or
- Procaine penicillin 1.5g IM daily for at least 3 days.

### Using skin barrier products and topical medication concurrently

 Personal communication with Dr Jill Campbell - [jill.campbell@qut.edu.au](mailto:jill.campbell@qut.edu.au)

No empirical evidence is available to guide the concurrent use of skin barrier products and topical medications for persons with IAD. It is possible that the use of ointment or cream based medications may affect the efficacy of the skin barrier product, or the efficacy of the topical medication may be adversely affected by the skin barrier product.

Use clinical judgement to assess individual circumstances when considering use of these products alone or concurrently. Anecdotal and expert opinion suggests that topical medication should be applied immediately following continence clean up, and waiting 30 minutes before applying the barrier product to allow for absorption of the medication. Ongoing clinical assessment is required to evaluate the response to treatment. Referral to a continence advisor or wound consultant is recommended if combination therapy with skin barrier products and topical medication is considered.

## Glossary

|   |  |
|---|--|
| <b>Bulla</b>                              | Circumscribed/defined lesion > 1 cm in diameter that contains liquid (clear, serous or haemorrhagic) - a large blister   |
| <b>Candidiasis</b>                        | Infection caused by the yeast <b>Candida</b> . Can cause vaginal yeast infections, diaper rash, intertrigo (skin rashes that emerge in moist, warm folds of skin), and thrush (white patches inside the mouth and throat). |
| <b>Denudation</b>                         | Loss of epidermis caused by exposure to urine, faeces, body fluids, wound exudate or friction.   |
| <b>Erosion</b>                            | Loss of either a portion of or the entire epidermis.   |
| <b>Excoriation</b>                        | A loss of the epidermis and a portion of the dermis due to scratching or an exogenous injury.  |
| <b>Maceration</b>                         | An appearance of surface softening due to constant wetting – frequently white.   |
| <b>Papule</b>                             | An elevated, solid, palpable lesion that is ≤ 1 cm in diameter.  |
| <b>Pustule</b>                            | A circumscribed lesion that contains pus.  |
| <b>Scale</b>                              | A visible accumulation of keratin, forming a flat plate or flake.  |
| <b>Swelling</b>                           | Enlargement due to accumulation of oedema or fluid, including blood.   |
| <b>SGLT2 inhibitor</b><br>(or gliflozins) | Class of medications that inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. Used in the treatment of type II diabetes mellitus.   |
| <b>Vesicle</b>                            | Circumscribed/defined lesion ≤ 1 cm in diameter that contains liquid (clear, serous or haemorrhagic) - a small blister.  |

For further information or to provide feedback:

- Regional Wounds Victoria: Website: <http://infectioncontrol.grampianshealth.org.au/index.php/health-resources/regional-wounds-victoria>
- VICNISS Coordinating Centre: Website: <https://www.vicniss.org.au/> Phone: 9342 9333

## References

1. Beeckman D., Van den Bussche K., Alves P., Beele H., Ciprandi G., Coyer F., de Groot T., De Meyer D., Dunk A.M., Fourie A., Garcia-Molina P., Gray M., Iblasi A., Jelnes R., Johansen E., Karadağ A., LeBlanc K., Kis Dadara Z., Long M.A., Meaume S., Pokorna A., Romanelli M., Ruppert S., Schoonhoven L., Smet S., Smith C., Steinger A., Stockmayr M., Van Damme N., Voegeli D., Van Hecke A., Verhaeghe S., Woo K. and Kottner J. The Ghent Global IAD Categorisation Tool (GLOBIAD). Skin Integrity Research Group - Ghent University 2017. Available to download from [www.UCVVGent.be](http://www.UCVVGent.be)
2. Beeckman D, Van Damme N, Schoonhoven L, et al. Interventions for preventing and treating incontinence-associated dermatitis in adults (Review). Cochrane Database of Systematic Reviews 2016 issue 11. Art. No.: CD011627.
3. National Pressure Ulcer Advisory Panel (NPUAP), European Pressure Ulcer Advisory Panel (EPUAP) and Pan Pacific Pressure Injury Alliance (PPPIA). Prevention and Treatment of Pressure Ulcers: Clinical Practice Guideline 2014.
4. Dermatology Expert Groups. Therapeutic guidelines: Dermatology Version 4 2014 Therapeutic Guidelines Ltd; Melbourne.
5. Australian Medicines Handbook. 2018 Australian Medicines Handbook Pty Ltd; Adelaide.
6. AMH Aged Care Companion. 2018 Australian Medicines Handbook Pty Ltd; Adelaide.